Evropska unija - slovenščina - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - drugi dermatološki preparati - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

meda pharma gmbh & co. kg - pimekrolimus - krema - pimekrolimus 10 mg / 1 g - pimekrolimus

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gsk d.o.o., ljubljana - alitretinoin - kapsula, mehka - alitretinoin 10 mg / 1 kapsula - alitretinoin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gsk d.o.o., ljubljana - alitretinoin - kapsula, mehka - alitretinoin 30 mg / 1 kapsula - alitretinoin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

meda pharma gmbh & co. kg - pimekrolimus - krema - pimekrolimus 10 mg / 1 g - pimekrolimus

Evropska unija - slovenščina - EMA (European Medicines Agency)

zoetis belgium sa - oclacitinib maleat - sredstva za dermatitis, razen kortikosteroidov - psi - - treatment of pruritus associated with allergic dermatitis in dogs. - treatment of clinical manifestations of atopic dermatitis in dogs.

Evropska unija - slovenščina - EMA (European Medicines Agency)

zoetis belgium sa - lokivetmab - drugi dermatološki preparati, sredstva za dermatitis, razen kortikosteroidi - psi - zdravljenje kliničnih manifestacij atopičnega dermatitisa pri psih.

Evropska unija - slovenščina - EMA (European Medicines Agency)

leo pharma a/s - takrolimus - dermatitis, atopic - drugi dermatološki preparati - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. nastale štiri ali večkrat na leto), ki so imeli začetni odziv na največ šest tednov, zdravljenje dvakrat na dan tacrolimus mazilo (lezije, izbrisani, skoraj izbrisani, ali lahko vpliva).

Evropska unija - slovenščina - EMA (European Medicines Agency)

pfizer europe ma eeig  - crisaborole - dermatitis, atopic - drugi dermatološki preparati - staquis je indiciran za zdravljenje blage do zmerno atopijskega dermatitisa pri odraslih in pediatričnih bolnikih od 2. leta starosti s ≤ 40% telesne površine (bsa), ki.

Evropska unija - slovenščina - EMA (European Medicines Agency)

almirall, s.a. - lebrikizumab - dermatitis, atopic - drugi dermatološki preparati - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.